The effects of chronic naltrexone treatment in young autistic children: A double-blind placebo-controlled crossover study

Biological Psychiatry

Volumn 39, Issue 12, 1996, Pages 1023-1031

  Willemsen Swinkels, Sophie H N ^a   Buitelaar, Jan K ^a   Van Engeland, Herman ^a  

^a Department of Child Psychiatry ^*

Author keywords

Autism; Locomotor activity; Naltrexone; Opiate antagonist; Social behavior; Endorphins

Indexed keywords

NALTREXONE; PLACEBO;

ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERACTIVITY; INFANTILE AUTISM; IRRITABILITY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0030010710     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00297-9     Document Type: Article

References (42)

1. Aman MG, Singh NN, Stewart AW, Field CJ (1985): The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491.
2. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev (DSM-III-R). Washington, DC: American Psychiatric Press.
3. Asleson GS, Herman BH, Borghese IF, Allen RP, Arthur-Smith A (1991): Effects of acute naltrexone on locomotor activity in autistic children. Soc Neurosci Abstr 17:1346.
4. Berridge CW, Arnsten AFT, Foote SL (1993): Noradrenergic modulation of cognitive function: Clinical implications of anatomical, electrophysiological and behavioural studies in animal models. Psychol Med 23:557-564.
5. Borbely AA (1986): New techniques for the analysis of the human sleep-wake cycle. Brain Dev 8:482-488.
6. Borghese IF, Herman BH, Asleson GS, Chantoor I, Benoit MB, Papero P, McNulty G (1991): Effects of acutely administered naltrexone on social behavior of autistic children. Soc Neurosci Abstr 17:1252.
7. Borghese IF, Herman BH, Anselmi LS, Asleson G, Lukens E, Benoit MB, Chantoor I, Papero P (1993): Effects of acutely and chronically administered naltrexone on social behavior and language of children with autism. Soc Neurosci Abstr 19:1785.
8. Buitelaar JK (1993): Endogenous opioids and their putative role in disturbances of social behavior, in particular in autism. In Macher JP, Crocq MA (eds), The Bio-Clinical Interface, Proceedings of the IXth Conference. Rouffach, France, September 23-26, 1992. Amsterdam: Elsevier Science Publishers B.V.
9. Buitelaar JK, Van Engeland H, Van Ree JM, De Wied D (1990): Behavioral effects of ORG 2766, a synthetic analog of the adrenocorticotrophic hormone (4-9) in 14 outpatient autistic children. J Autism Dev Disord 20:467-478.
10. Buitelaar JK, Van Engeland H, De Kogel CH, De Vries H, Van Hooff J, Van Ree J (1992a): The adrenocorticotrophic hormone (4-9) analog ORG-2766 in autistic children: Effects on the organization of behavior. Biol Psychiatry 31:1119-1129.
11. Buitelaar JK, Van Engeland H, De Kogel CH, De Vries H, Van Hooff J, Van Ree JK (1992b): The adrenocorticotrophic hormone (4-9) analog ORG-2766 benefits autistic children -Report on a second controlled clinical trial. J Am Acad Child Adolesc Psychiatry 31:1149-1156.
12. Campbell M, Adams P, Small AM, McVeigh Tesch L, Curren EL (1988): Naltrexone in infantile autism. Psychopharmacol Bull 24:135-139.
13. Campbell M, Overall JE, Small AM, Sokol MS, Spencer EK, Adams P, Foltz RL, Monti KM, Perry R, Nobler M, Roberts E (1989): Naltrexone in autistic children: An acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 28:200-206.
14. Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Choroco MC (1990): Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacol Bull 26:130-135.
15. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M (1993): Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32:1283-1291.
16. Dokla CPJ (1992): Naloxone reduces social locomotor activity in rats. Pharmacol Biochem Behav 43:1183-1193.
17. Gillberg C, Terenius L, Hagberg B, Witt-Engerström I, Eriksson I (1990): CSF beta-endorphins in childhood neuropsychiatric disorders. Brain Dev 12:88-92.
18. Herman BH, Hammock MK, Arthur-Smith A, Egan J, Chatoor I, Zelnik N, Corradine M, Appelgate K, Boeckx RL, Sharp SD (1986): Role of opioid peptides in autism: Effects of acute administration of naltrexone. Soc Neurosci Abstr 12:1172.
19. Herman BH, Asleson GS, Borghese IF, Chantoor I, Benoit MB, Powell A, Papero P, Allen RP, McNulty G (1991): Acute natrexone in autism: Selective decreases in hyperactivity. In Scientific Proceedings, 38th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington DC: AACAP, p 52.
20. Herman BH, Asleson G, Lukens E, Borghese I, Anselmi L, Allen RP, Benoit MB, Chatoor I, Papero P (1993): Acute and chronic naltrexone decreases the hyperactivity of autism. Soc Neurosci Abstr 19:1785.
21. Jacobson NS, Truax P (1991): Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychology 59:12-19.
22. Katz RJ (1988): Endorphins, exploration and activity. In Rodgers RJ, Cooper SJ (eds), Endorphins, Opiates and Behavioural Processes. Chichester: John Wiley & Sons Ltd., pp 249-267.
23. Kolmen BK, Feldman HM, Handen BL, Janosky JE (1995): Naltrexone in young autistic children: A double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 34:223-231.
24. Leboyer M, Bouvard MP, Dugas M (1988): Effects of naltrexone on infantile autism. Lancet 26:715.
25. Leboyer M, Bouvard MP, Lensing P, Launay J-M, Tabuteau F, Arnaud P, Waller D, Plumet M-H, Recasens C, Kerdelhue B, Dugas M, Panksepp J (1990): Opioid excess hypothesis of autism: A double-blind study of naltrexone. Brain Dysfunction 3:285-298.
26. Leboyer M, Bouvard MP, Launay J, Tableau F, Waller D, Dugas M, Kerdelhue B, Lensing P, Panksepp J (1992): Brief report: A double-blind study of naltrexone in infantile autism. J Autism Dev Disord 22:309-319.
27. Leboyer M, Bouvard MP, Recasens C, Philippe A, Guilloud-Bataille M, Bondoux D, Tabuteau F, Dugas M, Panksepp J, Launay J (1994): Difference between plasma N-and C-terminally directed β-endorphin iramunoreactivity in infantile autism. Am J Psychiatry 151:1797-1801.
28. Marshburn EC, Aman MG (1992): Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. J Autism Dev Disord 22: 357-373.
29. Matson JL, Rotatori AF, Helsel WJ (1985): Special Feature: Development of a rating scale to measure social skills in children: The Matson Evaluation of Social Skills with Youngsters (MESSY). Psychopharmacol Bull 21:855-868.
30. National Institute of Mental Health (1985): Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21: 839-842.
31. Noldus LPJJ (1991): The observer: A software system for collection and analysis of observational data. Behav Res Methods Instruments & Computers 23:415-429.
32. Panksepp J (1979): A neurochemical theory of autism. Trends Neurosci 2:174-177.
33. Panksepp J, Sahley TL (1987): Possible brain opioid involvement in disrupted social intent and language development of autism. In Schopler E, Mesibov GB (eds), Neurobiological Issues in Autism. New York: Plenum Press, pp 357-372.
34. Panksepp J, Leboyer M, Bouvard MP, Lensing P (1994): Naltrexone in infantile autism-response. J Autism Dev Disord 24:238-239.
35. Ross DL, Klykylo WM, Hitzemann R (1987): Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. Pediatr Neurol 3:83-86.
36. Sandman CA, Barron JL, Chicz-DeMet A, DeMet EM (1991): Brief report: Plasma β-endorphin and cortisol levels in autistic patients. J Autism Dev Disord 21:83-87.
37. Schopler E, Reichler RJ, DeVellis RF, Daly K (1980): Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 10:91-103.
38. Strahlendorf HK, Strahlendorf JC, Barnes CD (1980): Endorphin-mediated inhibition of locus coeruleus neurons. Brain Res 191:284-288.
39. Walters AS, Barrett RP, Feinstein C, Mercurio A, Hole WT (1990): A case report of naltrexone treatment of self-injury and social withdrawal in autism. J Autism Dev Disord 20:169-176.
40. Weizman R, Gil-Ad I, Dick J, Tyano S, Szekely GA, Laron Z (1988): Low plasma immunoreactive β-endorphin levels in autism. J Am Acad Child Adolesc Psychiatry 27:430-433.
41. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, Van Engeland H (in press): A placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res.
42. Wing L, Gould J (1979): Severe impairments of social interaction and associated abnormalities in children: Epidemiology and classification. J Autism Dev Disord 9:11-29.